Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 87

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 8
Chunk 87
---
-term debt$502 $500 $505 $502 Long-term debt16,853 14,373 15,500 13,109 As of June 27, 2025 and December 31, 2024, short and long-term borrowings were categorized as Level 1.  The fair value of long-term borrowings was based on quoted market prices.  The difference between the fair value and the carrying amounts of long-term borrowings is attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the incurrence of the borrowing.  The fair values of borrowings with original maturities of one year or less, as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable generally approximate their carrying amounts due to the short-term maturities of these instruments.

15

NOTE 10.  FINANCING

As of June 27, 2025, the Company was in compliance with all of its debt covenants.  The components of the Company’s debt were as follows ($ in millions):Outstanding AmountDescription and Aggregate Principal AmountJune 27, 2025December 31, 2024Euro-denominated commercial paper (€932 million and €931 million, respectively)(a)$1,091 $965 3.35% senior unsecured notes due 9/15/2025 ($500 million) (the “2025 U.S. Notes”)(b)500 500 0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”)(c)1,463 1,293 2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”)(b)936 828 0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”)(d)213 195 1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”)(e)701 620 0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”)(c)1,460 1,291